Safety and efficacy of nintedanib as second-line therapy for patients with differentiated or medullary thyroid cancer progressing after first-line therapy. A randomized phase II study of the EORTC Endocrine Task Force (protocol 1209-EnTF)

Supporters

Support the authors with ResearchCoin

Tip RSC

Journal

Frontiers in Endocrinology

Topics

Medicine

Cancer Oncology

Internal Medicine

Endocrinology, Diabetes And Metabolism

Pulmonary And Respiratory Medicine

Show all topics

DOI

10.3389/fendo.2024.1403687

License

CC-BY